2023 World Conference on Lung Cancer (Posters)-EP08.02. Neoadjuvant Immune Checkpoint Inhibitor plus Chemotherapy for Resectable Non-small Cell Lung Cancer in Real World

EP08.02. Neoadjuvant Immune Checkpoint Inhibitor plus Chemotherapy for Resectable Non-small Cell Lung Cancer in Real World - PDF(Abstract)

Back to course

Pdf Summary

This study analyzed the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in patients with resectable non-small cell lung cancer (NSCLC) in a real-world setting. The study included 32 patients who received treatment at the Affiliated Hospital of Zunyi Medical University from November 2020 to November 2022. The neoadjuvant regimen consisted of programmed cell death protein-1 (PD-1) inhibitors, either sintilimab or tislelizumab, in combination with platinum-based chemotherapy. The primary endpoint was major pathological response (MPR), and secondary endpoints included objective remission rate (ORR), pathological complete remission (pCR), clinical down staging rate, and surgical outcomes.<br /><br />The results showed that 59.38% of patients achieved MPR, 50.00% achieved pCR, and 87.50% had an ORR. The descending rate occurred in 87.50% of patients. The surgical outcomes were encouraging, with 96.88% of patients undergoing VATS switched to thoracotomy and a 93.75% R0 resection rate. The median surgery time was 215 minutes, and there were no 30-day or 90-day mortalities.<br /><br />Adverse events (AEs) were observed in 73 patients during the treatment period, with the majority being grade 1-2 AEs. The study concluded that neoadjuvant immunotherapy combined with chemotherapy is both feasible and safe for the treatment of resectable NSCLC, although further confirmation is needed through prospective clinical trials.<br /><br />Overall, this real-world study adds to the growing body of evidence supporting the use of neoadjuvant immunotherapy in combination with chemotherapy for resectable NSCLC. The results demonstrate a high response rate and positive surgical outcomes, with acceptable tolerability. However, more research is still needed to validate these findings in larger, prospective clinical trials.

Asset Subtitle

Cheng Chen

Meta Tag

Speaker Cheng Chen

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

neoadjuvant immunotherapy

chemotherapy

non-small cell lung cancer

efficacy

safety

real-world setting

PD-1 inhibitors

major pathological response

objective remission rate

pathological complete remission